Table 3 Univariate and multivariate Cox proportional hazards analysis of OS and DFS for patients with CRC in the FUSCC cohort
Variablesa | OS | DFS | ||||||
|---|---|---|---|---|---|---|---|---|
Univariate analysis | P b | Multivariate analysis | P b | Univariate analysis | P b | Multivariate analysis | P b | |
HR (95 % CI) | Â | HR (95 % CI) | Â | HR (95 % CI) | Â | HR (95 % CI) | Â | |
Age (years) | ||||||||
  ≤ 60 | 1.000 | 0.367 | 1.000 | 0.564 | 1.000 | 0.593 | 1.000 | 0.633 |
  > 60 | 1.224 (0.789–1.900) |  | 1.154 (0.709–1.879) |  | 1.115 (0.749–1.661) |  | 1.113 (0.717–1.730) | |
Genderb | ||||||||
 Male | 1.000 | 0.418 | 1.000 | 0.493 | 1.000 | 0.238 | 1.000 | 0.305 |
 Female | 0.829 (0.526–1.306) |  | 0.843 (0.518–1.374) |  | 0.781 (0.518–1.178) |  | 0.793 (0.509–1.235) | |
Tumor location | ||||||||
 Colon | 1.000 | 0.061 |  |  | 1.000 | 0.223 |  |  |
 Rectum | 0.658 (0.424–1.020) |  |  |  | 0.784 (0.529–1.160) |  |  | |
Histological type | ||||||||
 Adenocarcinoma | 1.000 | 0.781 |  |  | 1.000 | 0.765 |  |  |
 Mucinous/SRCC | 0.867 (0.317–2.369) |  |  |  | 0.872 (0.355–2.143) |  |  | |
T stage | ||||||||
 Tis-T2 | 1.000 | <0.001 | 1.000 | 0.017 | 1.000 | <0.001 | 1.000 | 0.032 |
 T3 | 4.450 (0.975–20.312) |  | 6.329 (1.325–30.238) |  | 2.979 (0.971–9.138) |  | 3.471 (1.074–11.221) | |
 T4 | 10.534 (2.581–42.992) |  | 8.734 (1.948–39.161) |  | 6.524 (2.390–17.805) |  | 4.282 (1.443–12.710) | |
N stage | ||||||||
 N0 | 1.000 | <0.001 | 1.000 | 0.269 | 1.000 | <0.001 | 1.000 | 0.089 |
 N1 | 2.770 (1.537–4.992) |  | 2.011 (0.982–4.117) |  | 2.927 (1.721–4.979) |  | 2.251 (1.202–4.215) | |
 N2 | 4.146 (2.336–7.357) |  | 1.931 (0.903–4.130) |  | 4.212 (2.510–7.069) |  | 1.968 (0.984–3.934) | |
M stage | ||||||||
 M0 | 1.000 | <0.001 | 1.000 | 0.024 | 1.000 | <0.001 | 1.000 | <0.001 |
 M1 | 9.094 (5.757–14.367) |  | 2.833 (1.137–6.083) |  | 10.198 (6.648–15.642) |  | 4.377 (1.999–9.585) | |
Pathological grading | ||||||||
 Well/moderate | 1.000 | 0.378 |  |  | 1.000 | 0.729 |  |  |
 Poor/anaplastic | 1.278 (0.762–2.144) |  |  |  | 1.137 (0.706–1.832) |  |  | |
 Unknown | 0.576 (0.180–1.836) |  |  |  | 0.784 (0.317–1.941) |  |  |  |
Venous invasion | ||||||||
 Negative | 1.000 | <0.001 | 1.000 | 0.987 | 1.000 | <0.001 | 1.000 | 0.55 |
 Positive | 2.448 (1.578–3.796) |  | 0.986 (0.578–1.681) |  | 2.216 (1.492–3.291) |  | 0.760 (0.464–1.246) | |
 Unknown | 1.043 (0.143–7.587) |  | 1.163 (0.154–8.756) |  | 0.813 (0.112–5.884) |  | 0.821 (0.110–6.136) | |
Nervous invasion | ||||||||
 Negative | 1.000 | 0.059 |  |  | 1.000 | 0.008 | 1.000 | 0.199 |
 Positive | 1.641 (0.981–2.743) |  |  |  | 1.186 (1.175–2.949) |  | 1.375 (0.846–2.237) | |
No. of LNs dissected | ||||||||
  < 12 | 1.000 | 0.249 |  |  | 1.000 | 0.297 |  |  |
  ≥ 12 | 0.719 (0.410–1.260) |  |  |  | 0.757 (0.449–1.276) |  |  | |
MMR status | ||||||||
 MMR-proficient | 1.000 | 0.726 |  |  | 1.000 | 0.792 |  |  |
 MMR-deficient | 1.084 (0.692–1.696) |  |  |  | 0.947 (0.632–1.418) |  |  | |
CEA (μl/ml) | ||||||||
  ≤ 5 | 1.000 | <0.001 | 1.000 | 0.041 | 1.000 | <0.001 | 1.000 | 0.096 |
  > 5 | 2.468 (1.572–3.875) |  | 1.386 (0.824–2.331) |  | 2.768 (1.845–4.152) |  | 1.529 (0.956–2.444) | |
 Unknown | 2.850 (1.118–7.265) |  | 3.513 (1.292–9.558) |  | 2.472 (0.979–6.246) |  | 2.230 (0.848–5.863) | |
Adjuvant chemotherapy | ||||||||
 Yes | 1.000 | <0.001 | 1.000 | 0.019 | 1.000 | <0.001 | 1.000 | 0.366 |
 No | 0.670 (0.315–1.425) |  | 1.835 (0.735–4.584) |  | 0.568 (0.281–1.146) |  | 1.419 (0.609–3.307) | |
 Unknown | 8.344 (5.142–13.542) |  | 3.130 (1.345–7.282) |  | 6.990 (4.495–10.870) |  | 1.645 (0.755–3.584) | |
TILs-PD-1 | ||||||||
 Low | 1.000 | 0.007 | 1.000 | 0.006 | 1.000 | 0.003 | 1.000 | 0.015 |
 High | 0.500 (0.302–0.828) |  | 0.480 (0.283–0.814) |  | 0.502 (0.319–0.789) |  | 0.559 (0.350–0.893) | |
TCs-PD-L1 | ||||||||
 Low | 1.000 | 0.027 | 1.000 | 0.852 | 1.000 | 0.005 | 1.000 | 0.66 |
 High | 0.606 (0.389–0.944) |  | 1.048 (0.639–1.719) |  | 0.558 (0.373–0.835) |  | 0.904 (0.577–1.417) | |